Your browser doesn't support javascript.
loading
Enteroendocrine and adipokine associations with type 2 diabetes: Phenotypic risk scoring approaches.
Cox, Amanda J; Zhang, Ping; Bowden, Donald W; Devereaux, Benedict; Davoren, Peter M; Cripps, Allan W; West, Nicholas P.
Afiliação
  • Cox AJ; Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.
  • Zhang P; School of Medical Science, Griffith University, Southport, Queensland, Australia.
  • Bowden DW; Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.
  • Devereaux B; Centre for Diabetes Research and Department of Biochemistry, Wake Forest School of Medicine, Winston Salem, North Carolina, USA.
  • Davoren PM; Digestive Diseases Queensland, Brisbane, Queensland, Australia.
  • Cripps AW; School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
  • West NP; Diabetes and Endocrinology, Gold Coast University Hospital, Southport, Queensland, Australia.
J Gastroenterol Hepatol ; 33(7): 1357-1364, 2018 Jul.
Article em En | MEDLINE | ID: mdl-29193302
BACKGROUND AND AIM: The contribution of gut-derived factors to the mechanisms linking obesity and metabolic disease remains under-investigated. The aim of the current study was to examine the associations between glucagon and enteroendocrine signaling and type 2 diabetes (T2D) using a derived risk score approach. To compare the relative importance of the enteroendocrine system, associations between adipokine measures and T2D were also investigated. METHODS: A total of 130 individuals with T2D and 161 individuals without T2D were included in the study. Circulating concentrations of enteroendocrine (glucagon, ghrelin, glucagon-like peptide-1, and gastric inhibitory peptide) and adipokine mediators (adiponectin, leptin, resistin, visfatin, and adipsin) were measured. Standard scores (Z-scores) were determined for each measure and enteroendocrine risk scores (ERS) and adipokine risk scores (ARS) calculated based on summation of the component measures. Associations between both the ERS and ARS and T2D status were assessed using logistic regression models. RESULTS: The ERS was significantly associated with T2D status in an adjusted model (odds ratio: 1.36; 95% confidence interval [CI]: 1.08-1.72; P = 0.009). Associations between the ARS and T2D status were not independent of age, sex, and body mass index (odds ratio: 1.21; 95%CI: 0.99-1.47; P = 0.06). Quantification of risk across ERS tertiles revealed that individuals with an ERS in the upper tertile were 10 times more likely (CI: 3.23-32.73; P < 0.001) to have T2D. CONCLUSIONS: These data support an association between enteroendocrine signaling and T2D. Use of the ERS as a potential tool for classifying individuals with metabolic syndrome as high or low risk for T2D development is being considered.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fenótipo / Glucagon / Polipeptídeo Inibidor Gástrico / Medição de Risco / Diabetes Mellitus Tipo 2 / Peptídeo 1 Semelhante ao Glucagon / Adipocinas / Grelina Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fenótipo / Glucagon / Polipeptídeo Inibidor Gástrico / Medição de Risco / Diabetes Mellitus Tipo 2 / Peptídeo 1 Semelhante ao Glucagon / Adipocinas / Grelina Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article